A cost-utility analysis of interferon beta for multiple sclerosis.

Abstract

A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assessment 1998; 2(4). Health Technology Assessment is indexed in Index Medicus/Medline and Excerpta Medica/Embase. Copies of the Executive Summaries are available from the NCCHTA web site (see overleaf).

Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom

“…Eleven articles from peer-reviewed journals met the inclusion criteria [14][15][16][17][18][19][20][21][22][23][24]. The one commissioned academic report to NICE [25], its addendum [26], and all five submissions to NICE [27][28][29][30][31] were also identified as relevant.…”

“…The one commissioned academic report to NICE [25], its addendum [26], and all five submissions to NICE [27][28][29][30][31] were also identified as relevant. Three articles by Parkin et al [14], McNamee and Parkin [15], and Parkin et al [16] described the same underlying model and because the article published in 2000 [16] provided a less detailed summary, the primary reports used for data extraction were the original publication from 1998 [14] and the update incorporating new data published in 1999 [15]. Two articles by Bose et al [19,20] were found to describe the same model, and data were initially extracted from the 2001 article [19] and then checked against the 2002 article [20].…”

“…Most reports up to 2003 did not report quantities separately to unit costs [17][18][19][20][21][22][23]25,26]. Likewise, none of the models before the ScHARR model reported probabilistic sensitivity analyses [14][15][16][17][18][19][20][21][22].…”

“…There is diversity in modeling technique, model structure, input data, and assumptions across the six models developed before the ScHARR model [14][15][16][17][18][19][20][21][22]. In contrast, models developed after the ScHARR model converge with respect to the technique and basic structure.…”

“…Of the models published before the ScHARR model in 2003 [23], two appeared to be decision tree models (though were not explicit in stating their model type) [14][15][16]18], one described itself as semi-Markov [21], one simulated individual patients [19,20], whereas two used forms of regression analysis [17,22]. The decision tree and Markov-type models [14][15][16]18,21] used various cohort structures based on different subsets of EDSS scores.…”